A major announcement was made recently in the world of pharmaceuticals. The company known around the world as EUSA Pharma has named a new person to take over their coveted position of President Europe. It will be a man named Carsten Thiel.
He has nearly 30 years of experience in the industry and has worked for a number of the world’s biggest and most respected pharma companies. EUSA Pharma is focused on oncology. However, they also dabble in rare diseases as well. The management of the company said that they are very happy with the appointment of Carsten Thiel to this very pivotal role in the company. They are confident that he will do a great job for them.
There had been rumors circulating for the past several months that EUSA Pharma was going to be shaking up their organization by giving promotions to several of their key employees. However, it was only a rumor at that point. Carsten Thiel has said in several interviews that he relished the challenge of being the man in charge of such a big division. He has worked his entire career to have this level of responsibility.
Carsten Thiel is originally from the city of Berlin in the country of Germany. He went to college at the University of Bristol. This school can be found in the United Kingdom. Thiel decided to focus on studying organic chemistry. He then went on to get a degree in biochemistry.
Finally, he attained a molecular biology PhD from the Max Planck Institute for Biophysical Chemistry. After he graduated from college, he went on to work for Hoffman la-Roche. It was at this company that Carsten Thiel made a name for himself in the pharma industry. Carsten has been a respected person ever since then and his reputation has grown.
Dr. Carsten Thiel is an expert in the field of biotechnology, who shares the view that the commercialization of gene therapies has become feasible as a result of ever-increasing efficiency and lower overhead involved in implementing technological innovations..
Marc Beer is a renowned professional when it comes to pharmaceuticals and biotechnology. He is known for his 25 years of experience in the pharmaceutical industry, having created multiple successful companies in the past. Just this April, LumiNXT, which is a company that provides illumination products, announced that Marc Beer will be the new Chairman of its Board of Directors. Beer also holds leadership in a company called Renovia.
As the newest chairman of LumiNXT, Marc Beer expressed his happiness after he was trusted the position. Beer also mentioned how working with a group of dedicated surgeons and engineers is something that he is proud of. The company’s products are known for their proprietary technology, which helps surgeons perform their surgeries safely. According to Beer, LumiNXT has a bright future and believes that the company will be more involved when it comes to minimally invasive approaches.
LumeNXT offers surgical lighting which is self-powered and mountable to allow more customization during a procedure. With the company’s advanced technology, it is able to emit light directly in the wound to improve the visualization. However, as one of its important features., LumeNXT products have a technology in them that reduces the generated heat in order to avoid overheating. This way, the products of the company will promote safety and efficiency. Learn more: https://gazetteday.com/2018/10/marc-beer-funding-renovia/
LumeNXT co-founder Paul Rhyme is also positive in Marc Beer’s influence in the company. Rhyme believes that with Beer’s impressive track and high success in handling startups, he will also be able to help LumeNXT in the global commercial rollout. Rhyme is also announced as the new Chief Executive Officer of LumeNXT last April, and Beer has been one of the persons who made expressed their support to Rhyme.
Marc Beer is also currently one of the main driving forces of Renovia, which is a company that he co-founded in 2016 with Ramon Iglesias and Yolanda Lorie. The company received a successful Series A financing to support their goals. Renovia aims to develop products which help in the diagnosis and treatment of a condition known as Pelvic Floor Disorders. This affects a lot of women in the world, with a lot of cases left undetected because of no available diagnosis devices available. Renovia now released its first main products out of four. The product is called the Leva, which has been in the market.
As one of the most recognizable names in the industry, Marc Beer handled a lot of companies before. One of his ventures in the last decade is becoming the founding chairman of the Minerva Neurosciences, which is a company that focused on developing a treatment for the central nervous system diseases. Beer is also the former CEO of ViaCell before it was acquired by PerkinElmer in 2007. Follow Marc Beer on Facebook
The company LumeNXT Incorporated has named its newest member of the organization. Recently, it named longtime executive Marc Beer as its new Chairman of the Board. Beer will be joining a privately held company that focuses on developing specialized surgical illumination products. The products are used to perform minimally invasive surgeries. Once joining LumeN XT, Marc will bring his expertise and over two decades of experience in biotechnology, pharmaceuticals and medical device technology to LumeN XT.
Shortly after being named as the new chairman of LumeN XT, Marc Beer said that he is very proud to be working with a group of surgeons and engineers who are dedicated to using surgical illumination technology in order to perform surgery that is minimally invasive. He also said that he believes in the importance of the technology and products provided by LumeN XT as it will help enhance the effectiveness of minimally invasive surgical procedures.
It has been known that surgeons that use targeted illumination often find out that the technology helps enhance the vision, precision and flexibility whenever an operation is performed. As a result, it is a superior option compared to more traditional surgical techniques and approaches. LumeN XT has the distinct advantage of using advanced illumination that uses heat reduction. This helps improve the surgical precision as well as reducing costs.
The co founder of LumeN XT Paul Rhyne has said that Marc has been able to demonstrate a high level of success with numerous startup companies in the healthcare industry. He has been known to guide companies in a number of different phases or growth. Rhyne also said that Marc Beer has established a lot of experience in starting up companies and guiding them through the process of global growth as well as increasing their profitability.
Prior to joining LumeN XT, Marc Beer has spent the last few years as the founding chairman and chief executive officer of Renovia Incorporated. That company’s mission was to both discover and deliver a line of therapeutic devices. These devices were used to help treat pelvic floor disorders that women experience. Before founding and managing Renovia, Marc was the founder and chairman of another company called Minerva Neurosciences Incorporated. This company was one that provided clinical stage biopharmaceuticals. It developed products to help treat a number of disorders of the central nervous system. The company worked towards developing therapeutic options to psychological conditions such as insomnia, depression and schizophrenia. Learn more: http://professionaltales.com/the-voice-of-marc-beer-how-to-be-a-good-leader/
Throughout his career, Marc Beer has been involved in helping a number of biotechnology and healthcare companies become successful organizations. He was also actively involved in working in the biopharmaceutical field in which he looked to treat diseases and facilitate growth by issuing initial public offerings. Throughout his career, Marc has demonstrated valuable leadership skills that helped many companies reach their full potential.
Marc Beer, Founder and CEO of Renovia Inc., has been named by LumeNXT as the Chairman of its Board. LumeNXT is a leading company dedicated to the development of a proprietary surgical illumination solution for minimally invasive surgeries. He boasts more than 25 years of development as well as commercialization experience in devices, biotechnology, pharmaceuticals, as well as diagnostics.
According to Marc Beer, he is glad to be working with a committed and dedicated group of surgeons as well as engineers who have contributed a lot to the advancement of the field of surgical illumination including the LumeNXT proprietary technology which is playing a big role in safe performing of surgeries. As more surgeries are being carried out leveraging minimally invasive approaches, the importance of the platform will continue to suffice. Surgeons have testified to the efficiency of the technology and they have found that it enhances precision, visualization, as well as flexibility during surgical procedures as compared to traditional techniques.
LumeNXT’s advanced illumination platform serves as a heat reduction mechanism to enhance safety, low-cost disposable options, and surgical precision through enhanced visualization. According to Paul Rhyne, Co-Founder of LumeNXT, Marc Beer has achieved a lot in his career life establishing startup companies and helping them to grow. He has valuable experience in starting as well as guiding companies through global commercial rollout and lead them along the path to profitability.
Marc Beer founded Renovia Inc. with a mission to develop and provide innovative therapeutic and diagnostic devices to women affected by pelvic floor disorders. Formally, he was the founding chairman of Minerva Neurosciences Inc., a biopharmaceutical company which develops products to treat central nervous system diseases. The company performs multiple late-stage clinical trials and develops innovative therapeutic compounds for insomnia, schizophrenia, mood disorders, Parkinson’s disease, and major depressive disorders.
Previously, he held several leadership positions in the biopharmaceutical sector where he headed commercial launches addressing rare disease on a global growth, global scale, initial public offerings, acquisitions and many more. Marc Beer’s other previous positions include Founding Chairman of the board of Good Start Genetics, Inc., CEO of ViaCell, Erytech Pharma Board of Directors, Global Marketing Vice President at Genzyme, as well as other various sales and marketing positions at Abbot Laboratories. He served at the Mass Life Science Board of the Commonwealth of Massachusetts as a members. He also held a position at the Biotechnolgy Industry Organization (BIO) Emerging Companies Section Governing Board. Today, he serves as the Co-founder, chairman and CEO at Renovia Inc. He is a graduate from Miami University, Ohio. Recently, he successful closed $42 million in venture and debt for the women’s health startup. The money was used to develop and test four more new products. Learn more: https://renoviainc.com/
Marc Beer is the co-founder of Renovia Inc. alongside Ramon Iglesias and Yolanda Lorie. The Boston based Biotechnology Company has for the past two years been developing different diagnostic and therapeutic treatment products for the treatment of pelvic floor problems. The health disorder that primarily affects women, and also known as urinary incontinence, is estimated to affect over $250 million women in the world.
Barely 24 months after establishment, Renovia had already come up with a diagnosis and treatment for the pelvic floor health problem. A big percentage of the success here is credited to Marc Beer who is a blend of rich experience, expertise in pharmaceuticals helped speed up this process. The company’s first product referred to as Leva was approved by FDA in April for distribution and administration to patients. Renovia is expected to continue creating more products to address this disorder.
Raising $42 million
Recently, Marc Beer raised $42 million to help fund this startup healthcare company advance its research and drug development. The Series B round funding helped raise over $32 million in equity capital and $10 million in form of venture debt. Marc mentioned that these funds will be used in advancing clinical testing and pushing the different products they have in the pipeline towards FDA approval. More importantly, the funds will help speed up the finalization of the development and release of a new version of the Leva drug.
While March Beer did not speak choose not to reveal much about their pipeline products, he expressed his gratitude for the financial support offered by the leading healthcare investors. These include Longwood fund and OSF ventures and their contributions will help come up with better diagnostic tools for effective treatments and improvement of women health.
Marc Beer’s Background
Marc Beer has had close to three decades of experience in the biotechnology and pharmaceutical industry, most of which was spent in the development and commercialization of drugs and medical inventions. Before co-founding Renovia, he had worked with the Michigan-based Milliendo Therapeutics, ViaCell and Abbott Laboratories. He graduated with a Bachelor of Science from Miami University, Ohio.
Marc has had an excellent track record in technology and medicine and rose to prominence in the health industry after founding ViaCell. He helped manage the firm as its Chief executive officer and within two years, it had over 300 employees before going public in 2005. Marc would also play a key role in facilitating its acquisition by Perkin Elmer in 2007.
Beer also worked in various companies in the technology and medical world where he managed different projects including sales and marketing. The positions that he has held in his career were not only related to diagnostics and pharmaceutical products, but they also helped him know what people want and need most. He is using that experience in his work at Renovia Inc. Learn more: https://renoviainc.com/leadership/
Men and women have a pelvic floor. In the latter, the pelvic floor muscles include ligaments, nerves as well as connective tissues that support the bladder. All these tissues help to support the pelvic organ functions. For many, the pelvic floor doesn’t work as required. Almost a quarter of these women suffer pelvic floor disorders, and that’s why Marc Beer, the serving CEO of Renovia has stepped up to help complete the Series B Financing.
Marc Beer Chairs The Series B Funding to Support Women with Pelvic Floor Disorders
Marc Beer has a stellar reputation of changing startups into useful commercial enterprises that have strong financial muscles with the aim of achieving various strategic needs. He recently chaired the Series B Financing which raised about $42 billion for the research and development of urinary incontinence that affects many women. The funds will be used to develop affordable drugs for the same medical condition. Through Marc Beer, the funds were raised via an infusion that propelled the company towards receiving various funds from investment firms such as Ascension Ventures and Longwood Fund. The same funds will also be used in developing Revia which awaits the FDA approval. The new round of financing will assist the company to perfect their diagnostic systems for pelvic floor disorders by merging innovative technologies with value-added digital platforms. The merger will lead to reduced costs of treating pelvic floor disorders in women.
Marc Beer is a Great Business Originator
Marc Beer is a committed business professional with the unmatched commitment of transforming emerging businesses into profitable commercial enterprises. He then founded Revia Inc. Through his exemplary leadership, he’s been guiding the company towards initiating useful funding as well as the development of an FDA approved drug. The specialists will provide a broad range of diagnostic services to care for the sensitive matter. Over the years, Marc Beer has successfully founded various firms including ViaCell where he serves as the CEO. The company capitalizes on stem cell research. Under his leadership, the company received recognition from the NASQAD while its worker base tremendously grew within the few years of its founding. The move attracted big corporations such as PerkinElmer. After the acquisition of ViaCell, Marc Beer joined Erytech Pharma where he served as the board member. He additionally founded Good Start Genetics and served as the head of operations.
Marc Beer’s Professional Background and Experience
Marc Beer is a revered business developer with extensive experience in the pharmaceutical industry. He also doubles as a sales and marketing personnel. Prior to venturing in the startup industry, he served a vice president at Genzyme and oversaw the marketing unit. He is a holder of a bachelor’s degree in science and business studies. Learn more: https://renoviainc.com/